Valeritas V-Go demonstrates benefits compared to MDI therapy for type 2 diabetes
Valeritas presented clinical and economic outcomes for V-Go compared to standard multiple daily injections, or MDI, insulin therapy for treating people with type 2 diabetes. The results were presented at the annual meeting of the European Association for the Study of Diabetes, or EASD. This retrospective study was performed using administrative claims from the HealthCore Integrated Research Database during six years between July 1, 2011 to July 31, 2017 containing data from large U.S. commercial health plans. During 6-12 months of follow-up, both the V-Go and MDI cohorts experienced improvements in glycemic control relative to baseline. Importantly, the improvement in glycemic control for V-Go users was achieved with a 21% decline in insulin total daily dosage, as compared to MDI users. Additionally, the V-Go group spent an average of $1,287 less per patient in diabetes-related medication costs compared to the MDI group.